Date of this Version
Ndung’u JM, Boulange´ A, Picado A, Mugenyi A, Mortensen A, Hope A, et al. (2020) Trypa-NO! contributes to the elimination of gambiense human African trypanosomiasis by combining tsetse control with “screen, diagnose and treat” using innovative tools and strategies. PLoS Negl Trop Dis 14(11): e0008738. https://doi. org/10.1371/journal.pntd.0008738
Gambiense human African trypanosomiasis (g-HAT) is the chronic form of sleeping sickness caused by Trypanosoma brucei gambiense in West and Central Africa, while Trypanosoma brucei rhodesiense causes an acute form in eastern Africa. g-HAT is targeted for elimination as a public health problem by 2020 and 0 transmission by 2030 [1,2]. Control of g-HAT is largely based on identification and treatment of infected individuals, supplemented by control of the tsetse fly vectors . There has been growing evidence that when both tsetse control and case identification activities are carried out simultaneously in the same geographies, elimination of the disease is accelerated [4–6]. Here, we describe how the Trypa-NO! Partnership is using novel and classical tools to drive g-HAT elimination in an integrated approach, progress made, lessons learnt, and future directions.
The Trypa-NO! Partnership was established in September 2016 to support National Sleeping Sickness Control Programmes (NSSCP) in Chad, Coˆte d’Ivoire, Republic of Guinea, and Uganda in driving elimination of g-HAT by integrating tsetse control with screening, diagnosis, and treatment of cases. The Partnership goals are to drive to 0 the annual number of g- HAT cases reported in Coˆte d’Ivoire and Uganda by 2020 and reduce cases by 90% in the Republic of Guinea and Chad by 2022.